Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 8;108(8):djw030. doi: 10.1093/jnci/djw030

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2016. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — Global analysis of hepatocellular carcinoma (HCC) tumor perfusion during sorafenib treatment using contrast-enhanced ultrasound imaging. Representative parametric maps of peak enhancement (PE), an indicator of tissue blood volume, show changes in tumor perfusion in a (A) vehicle-treated and (B) sorafenib-treated mouse. Red represents regions of high PE, blue are areas of low PE, and black represents no perfusion. C) Average PE values decreased statistically significantly two weeks after sorafenib therapy (P < .001, †P < .001 vs pretreatment), but further changes were not statistically significant for the following weeks. No statistically significant changes occurred in vehicle-treated mice (P = .07) whereas a statistically significant change was observed between vehicle- and sorafenib-treated mice by week 2 (*P < .05). Vehicle control mice were sacrificed after week 2. D) Wash-in rate, used as an indicator of rate of blood flow, showed no statistically significant changes over time, including during periods of drug resistance. Statistically significant changes were only observed between pre- and post-treatment for both sorafenib (P < .001, †P < .001)- and vehicle (paired t test *P < .05)-treated groups. n = 4 (vehicle), n = 11 (sorafenib). Global perfusion changes were tested by repeated measures one-way analysis of variance. Error bars represent standard deviation.